INTRODUCTION
Renal function plays a critical role in the prognosis of patients with cirrhosis. [1] During the last decade, Child-Pugh score was challenged by the more efficient and objective MELD (Model for End-stage Liver Disease) score. [2, 3] This brought renal function, estimated by serum creatinine, at the foreground in the management of patients with cirrhosis, due to its weight in MELD score. [4] Studies showed that creatinine and creatinine-based equations are inaccurate in patients with cirrhosis, notably because of low muscular mass, edemas and interference of serum bilirubin levels with creatinine measurement. [5, 6] Recently, Francoz et al. showed that MDRD4 and CKD-EPI creatinine formulas significantly overestimated true GFR, [7] especially in patients with severe ascites. [8] 
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Serum cystatin C (CystC) synthesis is constant even in the setting of inflammation or neoplasm. [9, 10] Its concentration is independent of muscle mass, age and gender, and can be reliably determined even in case of hyperbilirubinemia. [11] In patient with cirrhosis, CystC based equations had better performance than creatinine-based equations to assess GFR. [12, 13] Recently, new equations to evaluate GFR based on standardized assays of serum creatinine and CystC (CKD-EPI creatinine and CKD-EPI cystatin C), or a combination of both, were reported to have improved performance in the estimation of GFR in patients with no liver disease. [14, 15] In cirrhotics, De Souza et al. showed that the CKD-EPI cystatin C equation was more accurate than other cystatin and creatinine-based equations in the measurement of GFR. [16] The assessment of renal function in candidates for LT has two goals: selecting patients with renal failure who could benefit from simultaneous liver-kidney transplantation, [7, 17] and determining the mortality risk of patients after LT. [18] Post-LT chronic kidney disease (CKD) is frequent and associated with increased mortality. [19, 20] Its main determinant is the presence of pretransplant CKD which may lead to post-transplant kidney failure, mainly when associated to the nephrotoxicity of anticalcineurin drugs and/or to other morbidities. [20] [21] [22] Using serum creatinine in a very large population, Nair et al. showed that pretransplant renal dysfunction was associated with a decrease in 2-year survival after liver transplantation (LT). [23] 
A precise estimation of renal function in LT candidates should result in unveiling those requiring an optimized management to prevent renal failure, and identifying the long-term impact of renal function on post-transplant survival.
The aim of the study was to assess the predictive value of GFR for long-term survival after liver transplantation when measured by reference to the new CKD-EPI equations.
Patients and Methods

Patients
All patients who underwent LT in our center from 01/2001 to 12/2011 were included except in case of previous LT, multiple organ transplantation or emergency LT (lack of pretransplant evaluation). Cystatin C measurement is part of routine pre-LT workup in our center since
2001.
Combined kidney-liver transplantation was discussed in patients with estimated GFR≤30 mL/min/1.73 m2 based on MDRD4. Patients with kidney-liver transplantation were not included in the study.
The study protocol conformed to the guidelines of the declaration of Helsinki and was approved by the ethics committee of the University Hospital of Rennes. 
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Biochemistry
Cystatin C was prospectively assessed -at the same time and on the same blood sample as serum creatinine -using the Siemens N-latex-Cystatin C kit with BNII-systems. Values obtained before the use of the international reference material for cystatin C (ERM-DA471/IFCC) were recalculated according to manufacturer's recommendations (correction factor of 1.11).
GFR was assessed according to MDRD4, MDRD-6, CKD-EPI cystatin C, CKD-EPIcreatinine, and CKD-EPI cystatin C-creatinine equations. [15, 24, 25] French policies precluding the record of ethnic background, GFR was determined assuming all patients were non Blacks. However evaluation of patient currently on the waiting list (N=87) and patient who underwent LT in 2013 (N=117), showed that lower than 1% of patient were black. Therefore we think that it would not significantly alter estimated GFR. 
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Follow up data
Follow up data were obtained from the local database and the National Biomedicine Agency (which conducts a mandatory follow-up for all transplanted patients at least once a year).
According to French law, the corresponding database was declared to the "national committee of Informatics and Freedom" (CNIL, n°96-025).
Patients lost to follow-up were considered dead. The main endpoint was death from any cause after LT. Causes of death were prospectively recorded as infections, cardio vascular events, cancers (including recurrence of HCC), liver-related (rejection, recurrence of initial liver disease), others causes, and undetermined.
Statistical analysis
Continuous data were expressed as median [first-third quartile]. Univariate analysis was performed using Chi square or Mann Whitney test as applicable.
Patient survival was determined for each KDOQI-group using univariate Kaplan-Meier analysis. Because of the low number of KDOQI stage 4 patients (N=8 using MDRD-4), stage 3 and 4 were merged for the Kaplan-Meier analysis. Differences between groups were compared using the Log Rank test.
Cox regression analysis was performed to assess the independent effects of pre-LT parameters on survival.
Data were analyzed using 22 d version of SPSS (SPSS Inc., Chicago, USA). P < 0.05 was considered significant with a two-tailed test.
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RESULTS
Patients
During the study period, 1049 patients underwent LT, of whom 104 had previous LT, 46
multiple-organ transplantation, and 113 emergency transplantation. Among the 786 eligible patients, the 682 who had cystatin C measurement available at pretransplant assessment constituted the study population.
Clinical characteristics of the population are presented in Median time between evaluation and liver transplantation was 17 weeks.
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KDOQI groups according to estimated GFR
Distribution and clinical characteristics of patients according to KDOQI classification using CKD-EPI cystatin C are presented in Table 1 .
Factors associated with mortality
At univariate analysis, including all the clinical and biological variables from the donor and the recipient and the estimated GFR according to the different equations, serum cystatin C (p=0.001), donor age (p=0.005) and eGFR according to CKD-EPI cystatin C (p=0.003) and
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CKD-EPI creatinine cystatin C (p=0.009), and the type of the underlying liver disease (p=0.018) were associated with an increased risk of death.
Cox regression analysis with stratification on the causes of liver disease and adjusted for donor and recipient age, total bilirubin, prothrombin index, ascites stage, hepatocellular carcinoma and serum albumin showed that eGFR based on CKD-EPI cystatin C was the only variable significantly associated with death (p=0.029; HR 0.992; CI95%: 0.986-0.999) when introduced as a continuous variable into the model (Table 2 ). Similarly KDOQI stage based on CKD-EPI cystatin C was significantly associated with death (p = 0.025; HR 1.24; CI95%
1.02-1.50).
By contrast, eGFR was not significantly associated with death when calculated according to MDRD-4, MDRD-6, CKD-EPI creatinine-cystatin C and CKD-EPI-creatinine equations.
Long term survival
Kaplan-Meier survival estimates in the overall population at 1, 3 and 5 year were 89.6%, 80.9% and 76% respectively. 
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DISCUSSION
For the first time, the present study, based on a large number of patients with a wide range of liver and renal dysfunction, showed that renal function estimated using the CKD-EPI cystatin C equation is a prognostic factor of death after liver transplantation. By contrast creatininebased equations failed to be associated with long-term outcome.
Mindikoglu et al. and De Souza et al.
showed that cystatin C is a better marker of renal function in patient with cirrhosis, but they found conflicting results with respect to the more accurate equation to be used [16, 27] . Differences in the populations studied may explain these conflicting results. Mindikoglu et al. studied patients with hepatitis C-related cirrhosis without criteria for LT whilst De Souza et al. studied patients with end-stage alcoholic cirrhosis and with lower weight. Moreover sex ratios (male/female) differed markedly, which renders the comparison difficult, serum creatinine being lower in females than in males for a given GFR value. [28] However both studies concluded that cystatin C-based equations were more accurate than creatinine-based equations.
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Our population was similar to that of De Souza et al. [16] and we chose eGFR determined with CKD-EPI cystatin C equation as the reference. In agreement with these authors, our study shows that eGFR, is a prognostic factor of death when estimated using the CKD-EPI cystatin C but not the CKD-EPI creatinine cystatin C equation.
Of note, graft allocation policy changed during the study period (March 2007) due to the introduction of the MELD score, which has resulted in a higher proportion of patients transplanted with severe liver disease. The discrepancy between estimated GFR and true GFR determined by gold standard is significantly correlated to the severity of liver disease and the presence of ascites [16, 27] . However introducing the status regarding the allocation policy (before or after) in our multivariate analysis did not significantly change results regarding the prognostic value of any of the eGFR equations (data not shown).
One limitation of our study is the lack of a gold standard method to assess the true value of GFR. However our study aimed at assessing the clinical relevance of cystatin C as a prognosis tool for candidates to LT, but not the accuracy for GFR determination. Our study did not address the question of the most accurate method to assess renal function but it clearly showed that discrepancies in the prognostic value of creatinine-based and cystatin C-based equations were relevant. Another limitation of the study is the lack of post LT information regarding other disease that could influence long terme survival irrespectively of pre LT
GFR. The strength of our study is the large and homogenous population with a long followup of patients selected for LT.
With regard to the Cystatin C measurement technique, in order to reduce the variability between laboratories, the International Federation for Clinical Chemistry (IFCC) produced the reference material ERM-DA471/IFCC. [29] This certified material promoted to reduce concerns generated by different calibrators, is available to manufacturers of cystatin C reagents since 2010. However, a recent study showed that the variability in cystatin C determination persisted between manufacturers of in vitro diagnosis reagents [30] . These variations did not have any impact on the results of our study but for future studies, special attention should be paid to the technique used and to the calibration traceability to the ERM-DA471/IFCC reference material. Moreover this variability must be taken into account before cystatin C could be used to compare, or prioritize on the LT waiting list, patients from different centers.
The direct correlation between pretransplant renal function and long-term mortality was debated for a long time. Using the sole serum creatinine, several studies concluded to decreased post-LT survival in case of pre-LT renal failure [31] [32] [33] [34] . On the contrary, Brown et al., in a large number of patients, failed to find any impact of pre-LT renal function. [35] Similarly, Gonwa et al. showed that pre LT renal function has no effect on patient survival after LT when using creatinine-based eGFR. [36] This likely testifies of the low accuracy of serum creatinine determination to assess renal function.
The benchmark study by Nair et al. was able to demonstrate, using serum creatinine-based equations, that patients with impaired renal function had shorter long-term survival. [23] The very large population studied may have afforded the statistical power that was lacking to previous negative studies, and allowed for these conclusive results. It is noteworthy that our results based on a smaller population show that CKD-EPI-cystatin C eGFR is significantly associated with long term survival, suggesting a more accurate assessment of the impact of pretransplant renal function on survival after LT. Moreover, whereas calculated creatinine clearance was described as a categorical variable only in the study by Nair et al., [23] , our results show that CKD-EPI cystatin C eGFR is significantly associated with survival, whether it is considered as a categorical variable (KDOQI stage) or not. Referring to a continuous variable is likely to be more efficient when assessing a prognosis factor related to a physiological function. In their multivariate analysis, Nair et al. could assess the immediate and 2-year mortality, but not the 5-year mortality due to incomplete data for up to 47% of patient. [23] Thanks to the mandatory national follow-up in France, we had only 5 patients lost to follow-up and thus we were able to assess the impact of pretransplant renal function over the whole study period.
Accordingly to previous studies of similar sample size, [35, 36] we did not found significant correlation between creatinine-based eGFR and long-term survival. Although it was recently shown to be the more accurate eGFR equation in patients with cirrhosis, [7] MDRD-6 equation failed to show the impact of pretransplant renal function on survival after LT in our population.
This article is protected by copyright. All rights reserved. The use of CKD-EPI cystatin C equation in patients with cirrhosis may lead to overestimate the severity of renal disease in patients with normal renal function. [16] However, we think that, until better marker of GFR is routinely available, overestimation of renal disease is less harmful than its underestimation in candidates for LT.
In conclusion, we demonstrated that discrepancies between CKD-EPI cystatin C and creatinine -based equation are clinically relevant in patients with end-stage liver disease and that eGFR is predictive of long-term survival after liver transplantation if determined using the CKD-EPI cystatin C equation. This suggests that using cystatin C instead of creatinine to 
